small molecule

SUBVENITE

LAMOTRIGINE

Loss of exclusivityMay 2040latest FDA-listed patent expiry

CompanyOWP Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	SUBVENITE
Active ingredient	LAMOTRIGINE
Strength	10MG/ML
Dosage form	SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	September 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11596634	May 2040	use U-4273
11612566	May 2040	use U-4273
12629377	May 2040	product
12636289	May 2040	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.